Description: Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
Home Page: www.centessa.com
1 Ashley Road
Altrincham,
WA14 2DT
United Kingdom
Phone:
44 203 9206789
Officers
| Name | Title |
|---|---|
| Dr. Saurabh Saha M.D., Ph.D. | CEO & Director |
| Dr. David M. Chao Ph.D. | Chief Administrative Officer |
| Mr. John J. Crowley CPA | CFO and Principal Financial & Accounting Officer |
| Ms. Tia L. Bush | Chief Technology & Quality Officer |
| Ms. Kristen K. Sheppard Esq., J.D. | Senior Vice President of Investor Relations & Corporate Communications |
| Mr. Iqbal J. Hussain L.L.B. | General Counsel, Chief Compliance Officer & Corporate Secretary |
| Ms. Karen M. Anderson | Chief People Officer |
| Dr. Gregory M. Weinhoff M.B.A., M.D. | Chief Business Officer |
| Dr. Mario Alberto Accardi Ph.D. | President of the Orexin Program |
| Dr. Ellie Im M.D. | Senior Vice President of Clinical Development & Oncology |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.4458 |
| Price-to-Sales TTM: | 320.1021 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 76 |